Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease

The Journal of Prevention of Alzheimer s Disease(2025)10.1016/j.tjpad.2025.100259Source: DataRank Database

Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease is a research paper published in The Journal of Prevention of Alzheimer s Disease (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: goldTopics (8)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (52)

Javier Arbizu ORCID,Mercè Boada ORCID,Mircea Balasa ORCID,Karim Bennys ORCID,Marina Boban

Live enrichment

PubMed:40640062

National Institutes of Health

Grant: 5R01AG074258-02

Effects of the renin angiotensin system on MRI volumetric measures and cognitive function in the Alzheimer's disease process: the LookAHEAD study

Ministry of Education, Science and Technological Development of Republic of Serbia

Grant: 200110

Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200110 (University of Belgrade, Faculty of Medicine)

goldLicense: cc-by

publisherhttps://doi.org/10.1016/j.tjpad.2025.100259

publisherhttps://api.elsevier.com/content/article/PII:S227458072500202X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S227458072500202X?httpAccept=text/plain

repositoryhttps://research-information.bris.ac.uk/en/publications/05d6dd1e-db62-4886-b152-502fc1d9ed1b

repositoryhttps://pure.amsterdamumc.nl/ws/files/157361892/Comment-by-european-alzheimers-disease-consortium-eadc-investigators-on-the-negative-recommendation-of-the-chmp-on-th.pdf

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

[SDV] Life Sciences [q-bio]donanemab; Alzheimer disease; human; letter; marketing authorizationHuman medicineLetter to the EditorAlzheimer's Disease; donanemab; clinical trials: immunotherapy; amyloid; antibody; ARIAinfo:eu-repo/classification/ddc/610